Biotech company, supported by the Australian federal government, launching clinically-tested OTC topical for joint pain, stiffness & swelling including osteoarthritis in U.S. and worldwide
SAN FRANCISCO, CA – 9/14/2016 (PRESS RELEASE JET) — Millions of Americans and others worldwide who suffer from joint pain including osteoarthritis will soon get access to a remarkable topical product developed with natural botanical extracts but supported by gold standard scientific research. The patented technology in 4Jointz® has been published in leading peer-reviewed medical journals after successfully completing clinical studies in Australia and the U.S.
Australian-based Arthritis Relief Plus Ltd (ARP) is one of only eight companies recently selected by the Australian Government for its entrepreneurial “Landing Pad” program, a highly competitive initiative for fast-expanding companies with global potential, located at San Francisco tech accelerator RocketSpace. In August, RocketSpace, which helped Uber, Spotify and other startups, raised $336 million to expand into international markets.
“We’re thrilled to finally be able to offer this robustly-tested, natural OTC topical to Americans and sufferers worldwide for the first time,” said Andrew Loch, CEO of ARP (USA) Pty Ltd. “This product is unique—there’s nothing like it on the market—and we greatly appreciate the community support we are receiving for our launch of 4Jointz.”
Part of what got 4Jointz to where it is today, preparing for a major launch on Indiegogo, is strong support from people who have experienced significantly improved quality of life as a result of using 4Jointz.
“Living with pain is a pain,” says arthritis sufferer Bobbi Dobbs, who credaits 4Jointz with overcoming crooked, painful fingers and being able to play with her grandchildren again. “4Jointz has made such a difference in my life.”
Researchers and doctors familiar with the clinical trials have been equally impressed:
“The individuals that were experiencing success were extremely, extremely grateful,” said Oklahoma State University Professor Bert Jacobson, Ph.D. “They were almost wanting to kiss us, because they’ve been in such pain, and such misery for so long.”
“There are a lot of things out there that say they work,” said Dr. Brad Hayes, a chiropractic doctor, “but they really don’t work. This is something that works, and is something that you ought to try.”
4Jointz is a unique pain reliever that uses a novel, patented technology combining natural allantoin from a standardized safe comfrey extract with tannic acid and eucalyptus oil. It’s non- toxic, with no harmful side effects. There is no cooling or burning effect.
Its release into the U.S. market comes just in time for 77 million baby boomers, many of whom struggle with osteoarthritis (OA), or degenerative joint disease. According to the Center for Disease Control and Prevention (CDC), by 2040, an estimated 78 million Americans ages 18 years or older are projected to have doctor-diagnosed arthritis. Half will develop knee OA by age 85.
“In the US alone, over 60% of people over the age of 35 are living with joint pain,” states Persis Anderson, Founder of ARP. “With 10 years of research and development, the dedicated ARP team developed 4Jointz, determined to offer a product that combines the benefits of nature and scientific evidence into an OTC topical product that’s easy to use, fast acting, and above all effective, without the negative side effects of the current NSAIDs/pain medication on the market.”
Clinical trials of 4Jointz have shown reductions in pain, swelling and joint stiffness, and a concomitant increase in mobility and leg muscle strength for those suffering from osteoarthritis. A dual center, pivotal Phase III, randomized controlled trial of 4Jointz used for knee osteoarthritis pain (Prof. & Dr. Graeme Jones, Menzies Research Institute of Musculoskeletal Disease, and former Medical Director of Arthritis Australia) confirmed:
“Pain scores significantly reduced in the group who received 4Jointz compared to the group who received placebo after 12 weeks, using both the VAS and the KOOS pain scale.” This study confirmed the findings of a prior published pilot study by Oklahoma State University, a New Zealand trial and a considerable body of anecdotal evidence.
From regained flexibility in a “frozen” shoulder to taking fewer pain pills, avoiding an operation, resuming daily walks or a weekend golf game, testimonials of 4Jointz improving the lives of people living with arthritis are already legion. Now, Americans will have a chance to try this powerful topical treatment for themselves.
For more information, or to commit to the 4Jointz priority ordering visit www.4jointz.com.
Distributed by Press Release Jet
Company Name: 4JOINTZ
Contact Person: Chelsea Gladden
Phone: (310) 569-6586
Country: United States